Promotive excretion of causative agents of Yusho by one year intake of FBRA in Japanese people.

Thirty-six years have passed since the outbreak of Kanemi rice oil poisoning, namely, Yusho in the western Japan. However, even now the patients with Yusho have been still suffering from several objective and subjective symptoms. In order to improve or, if possible, to cure the such symptoms, the most important therapeutic treatment is considered to actively excrete the causative agents, that is, polychlorinated dibenzofurans (PCDFs) and polychlorinated dibenzo-p-dioxins (PCDDs) from the bodies of the patients and to reduce their body burdens. In rats, dietary fiber and chlorophyll have been shown to promote the fecal excretion of dioxins and to reduce their levels in rat liver. In this study, we examined whether such kinds of effect were also observed by FBRA, which was the health food and relatively rich with dietary fiber and chlorophyll, in nine married Japanese couples. As a result, concentrations of PCDFs and PCDDs on the lipid weight basis in the blood of the FBRA-intake group in which they took 7.0 to 10.5g of FBRA after each meal and three times a day for one year were more lowered than those in the blood of the non-intake group; Blood levels of PCDFs and PCDDs in the FBRA-intake group were decreased by 41.0 and 37.2%, respectively, and those decreases were 33.7 and 29.4% in the non-intake group. Their total body burdens just before and one year after the study were calculated on the assumptions that the body fat was also contaminated with these dioxins at their blood levels on the lipid weight basis and the content of body fat was 20% of the body weight. Then, we computed the average amounts in excretion of PCDFs and PCDDs from the body in both the FBRA-intake and non-intake groups. Consequently, the amounts of excretion of PCDFs and PCDDs in the FBRA-intake group were 1.81 and 1.74 times, respectively, greater than those in the non-intake group. Therefore, FBRA seemed to promote the fecal excretion of causative agents of Yusho, from the human body. We also expect FBRA to reduce their body burdens of patients with Yusho and to improve some objective and subjective symptoms of Yusho patients.